LAX-101 ( DrugBank: LAX-101 )


1 disease
IDDisease name (Link within this page)Number of trials
8Huntington disease5

8. Huntington disease


Clinical trials : 229 Drugs : 193 - (DrugBank : 60) / Drug target genes : 84 - Drug target pathways : 158
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-002088-98-PT
(EUCTR)
07/06/200616/03/2006Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseFull title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
INN or Proposed INN: Ethyl Icosapent
Other descriptive name: Ethyl-EPA
Amarin Neuroscience LtdNULLNot RecruitingFemale: yes
Male: yes
Portugal;Germany;United Kingdom;Spain;Italy
2EUCTR2005-002088-98-ES
(EUCTR)
29/12/200504/10/2005Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington.Full title of the trial : Estudio multicentrico, multinacional aleatorizado doble ciego con grupos paralelos y controlado con placebo de etil-EPA (etil eicosapentanoato) en pacientes con enfermedad de Huntington. HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: llt;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
Amarin Neuroscience LtdNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Portugal;Germany;United Kingdom;Spain;Italy
3EUCTR2005-002088-98-AT
(EUCTR)
01/12/200527/10/2005Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseFull title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
INN or Proposed INN: Ethyl-Icosapent
Amarin Neuroscience LtdNULLNot RecruitingFemale: yes
Male: yes
240Portugal;Spain;Austria;Germany;Italy;United Kingdom
4EUCTR2005-002088-98-GB
(EUCTR)
07/11/200518/08/2005Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseFull title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
Amarin Neuroscience LtdNULLNot RecruitingFemale: yes
Male: yes
Portugal;Germany;United Kingdom;Spain;Italy
5EUCTR2005-002088-98-DE
(EUCTR)
28/11/2006Full title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s DiseaseFull title of the trial : A multicentre, multi-national, double-blind, randomised, parallel group placebo-controlled trial of ethyl-EPA (ethyl-icosapent) in patients with Huntington’s Disease HUNTINGTON’S DISEASE
MedDRA version: 8.0;Level: LLT;Classification code 10010331
Product Name: Ethyl-EPA
Product Code: LAX-101
INN or Proposed INN: Ethyl-Icosapent
Amarin Neuroscience LtdNULLNot RecruitingFemale: yes
Male: yes
240Portugal;United Kingdom;Germany;Spain;Italy